Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine Conjugates

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1654873 since 2017-12-18T14:07:58Z

Published version:
DOI:10.1021/acsmedchemlett.7b00262

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Hetero-Nanoparticles by self-assembly of doxorubicin and cyclopamine conjugates
Hetero-Nanoparticles by self-assembly of doxorubicin and cyclopamine conjugates

Gaia Fumagalli,† Barbara Stella,‡ Ievgenia Pastushenko,§ Francesca Ricci,§ Michael S. Christodoulou,† Giovanna Damia,§ Davide Mazza,⊥ Silvia Arpicco,‡ Clelia Giannini,† Lavinia Morosi,¤ Franco Dosio,* Panagiota A. Sotiropoulou,*#, Daniele Passarella.*†

† Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
‡ Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino 10125, Italy
§ Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles (ULB), Brussels 1070, Belgium
# Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles (ULB), Brussels 1070, Belgium
§ IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Molecular Pharmacology, Milano 20156, Italy
¶ IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Molecular Pharmacology, Milano 20156, Italy
⊥ Centro di Imaging Sperimentale San Raffaele Scientific Institute, Milano 20132, Italy
Centro Europeo di Nanomedicina, Milano, 20133, Italy
¤ IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Cancer Pharmacology, Milano 20156, Italy

KEYWORDS Self-assembled-Nanoparticles, Cyclopamine, Doxorubicin, Drug toxicity, Cancer

ABSTRACT: The preparation of hetero-nanoparticles (NPs) with doxorubicin (DOXO) and cyclopamine (CYP) conjugates is presented. Biological evaluation on A431 cell lines confirms the maintenance of the activity of the parental drugs. The in vivo study shows that self-assembled NPs reduce tumour growth and toxicity of chemotherapy.

The use of self-assembled nanoparticles (NPs) is a challenging strategy that could result in a useful and smart approach to effectively treat cancer. In particular, we have recently reported the preparation of a novel class of squalene conjugates with paclitaxel, podophyllotoxin, camptothecin and epothilone A.2 The compounds obtained were characterized by a squalene tail that makes them able to self-assemble in water, and by a drug unit connected via a disulfide-containing linker to secure the release inside the cell. The need to trace the delivery of the nanoassemblies and to demonstrate the internalization of the drugs prompted us to prepare fluorescent hetero-nanoassemblies composed by a paclitaxel-squalene conjugate and fluorescein-squalene conjugate. Following the increasing interest of targeting cancer stem cells (CSCs)4,5 we moved forward and we demonstrated that cyclopamine – a hedgehog signaling pathway inhibitor4 and doxorubicin (DOXO) conjugates (Chart 1) with the aim to demonstrate the formation of hetero-NPs that could improve the performance given by the use of the simple parental drugs.

Chart 1. Structure of the used anticancer compounds. In red the anchor point for the functionalization.

Specifically, we decided to investigate the combination of cyclopamine-squalene (CYP-SQ) derivative 1, a conjugate found to be active on different types of cancer cells,6 with doxorubicin-squalene (DOXO-SQ) 2, described by Couvreur and some of us7 as able to improve the anticancer efficacy and the therapeutic index of DOXO (Chart 2).
pared by solvent displacement method, and no NPs aggregation was observed. Between the two squalene conjugates caused the formation of dispersed NPs.

Chart 2. Structure of the drug-squalene conjugates CYP-SQ and DOXO-SQ.

Hetero-NPs were obtained by mixing two squalene conjugates, CYP-SQ (1) and DOXO-SQ (2) (Chart 2), prepared according to the previously described approaches. All NPs were prepared by solvent-displacement method, using THF as organic solvent and without adding any surfactant. 1 and 2 were co-nanoprecipitated at 1:1, 5:1, 10:1 molar ratios (Table 1, NP1, NP2 and NP3 respectively) with a constant concentration of 1, giving a suspension of narrow monodispersed NPs. 1 and 2 were also separately nanoprecipitated to obtain NPs of CYP-SQ or DOXO-SQ alone (Table 1, NP0 and NP4). All the formulations were characterized in terms of mean diameter and zeta potential of the NPs. As showed in Table 1, CYP-SQ and DOXO-SQ alone spontaneously self-assembled in water forming NPs; however, DOXO-SQ NPs displayed a larger mean diameter of about 400 nm. When DOXO-SQ was formulated with an equimolar amount of CYP-SQ (NP1), the mean size drastically reduced from 400 to about 130 nm; in these conditions DOXO-SQ probably took a different sovramolecular organization and mutual interactions between the two squalene conjugates caused the formation of smaller nanoparticles. The addition of DOXO-SQ in various molar ratios did not influence the mean size of CYP-SQ NPs. The zeta potential of all NPs is highly positive; for NPs containing DOXO-SQ it is higher than the one of CYP-SQ-containing NPs. As reported in the Supporting Information, after 4-weeks storage at 4°C in water, no appreciable NPs size and/or zeta potential changes were detected by Dynamic Light Scattering (DLS) for all formulations (except for DOXO-SQ NP mean diameter) and no NPs aggregation was observed. After dilution with fetal bovine serum, NP1 did not show aggregation, even after 24 h at 4°C. On the contrary, the incubation in PBS 10 mM resulted in an increase of the NP1 mean diameter up to about 400 nm (700 nm after 24 h).

We next investigated in details the effect of the NPs in a cellular system with an activated Hedgehog pathway. Specifically, we used the human epidermoid carcinoma cell line A431, which carries a single point mutation in exon 23 of both alleles of Patched1 gene, resulting in a proline to leucine substitution and subsequent constitutive activation of the Hedgehog pathway. In a similar experimental setting, we studied the inhibition of proliferation and the apoptosis induction upon addition of CYP, DOXO and distinct ratios of CYP:DOXO, conjugate 1, conjugate 2 and distinct ratios of 1 and 2, free or assembled in NPs.

Table 1. NPs composition and characterization

<table>
<thead>
<tr>
<th>NPs</th>
<th>Composition</th>
<th>Components molar ratio and concentration</th>
<th>Mean diameter (nm ± S.D.)</th>
<th>Polydispersity index</th>
<th>Zeta potential (mV ± S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NP0</td>
<td>CYP-SQ</td>
<td>10 µM</td>
<td>127.8±0.723</td>
<td>0.106</td>
<td>+44.1±2.048</td>
</tr>
<tr>
<td>NP1</td>
<td>CYP-SQ/DOXO-SQ</td>
<td>1:1 (10 µM, 10 µM)</td>
<td>126.9±1.108</td>
<td>0.102</td>
<td>+61.6±4.18</td>
</tr>
<tr>
<td>NP2</td>
<td>CYP-SQ/DOXO-SQ</td>
<td>5:1 (10 µM, 2 µM)</td>
<td>129.4±1.589</td>
<td>0.109</td>
<td>+50.9±0.404</td>
</tr>
<tr>
<td>NP3</td>
<td>CYP-SQ/DOXO-SQ</td>
<td>10:1 (10 µM, 1 µM)</td>
<td>127.7±0.734</td>
<td>0.106</td>
<td>+56.8±2.66</td>
</tr>
<tr>
<td>NP4</td>
<td>DOXO-SQ</td>
<td>10 µM</td>
<td>395.4±6.739</td>
<td>0.122</td>
<td>-58.1±0.643</td>
</tr>
</tbody>
</table>

Figure 1. Effect on proliferation (A) and viability (B) in the A431 cancer cell line of cyclopamine, doxorubicin (reported as Parental drugs), compounds 1 and 2 not nanoprecipitated (reported as Conjugates) and nanoprecipitated compounds 1 and 2 (reported as NP). Concentration of the samples: NP1 (nanoprecipitated CYP-SQ = DOXO-SQ = 10 µM); NP2 (nanoprecipitated CYP-SQ = 10 µM, DOXO-SQ = 2 µM; NP3 (nanoprecipitated CYP-SQ = 10 µM, DOXO-SQ = 1 µM; 1:2 (1:1): CYP-SQ = DOXO-SQ = 10 µM; 1:2 (5:1): CYP-SQ = 10 µM, DOXO-SQ = 2 µM; 1:2 (10:1): CYP-SQ = 10 µM, DOXO-SQ = 2 µM; CYP:DOXO (1:1): CYP = DOXO = 10 µM, CYP:DOXO (5:1): CYP = 10 µM, DOXO = 2 µM, CYP:DOXO (10:1): CYP = 10 µM, DOXO = 1 µM. Statistical significance (Student’s t test) compared to Control: ns, p>0.01; *, p < 0.01; **, p<0.001; ***, p<0.0001.

DOXO alone at 10 µM (Figure 1A) was able to inhibit proliferation of more than 50%, and the addition of CYP further enhanced the cytostatic effect. The combination of 1 and 2 in 1:1 molar ratio also resulted in inhibition of proliferation, although to a lesser extent. Interestingly, when NP1 was used, cell proliferation is essentially entirely blocked. The same trend ap-
pears when investigating cell death, with CYP and derivative 1 not causing significant apoptosis, DOXO and derivative 2, alone or in combination with CYP or derivative 1 inducing apoptosis in 30-60% of the cells, while when assembled in NP1, practically all cells are dead (Figure 1B). Notably, while apoptosis is only observed at the 1:1 ratio of CYP:DOXO or of derivatives 1 and 2, inhibition of proliferation could be observed also at the ratio 5:1, potentially indicating that either lower concentration of DOXO or derivative 2 is necessary for the cytostatic function, or that apoptosis is a later stage event in this system. A time course analysis of proliferation and apoptosis would discriminate between the two options, but this is out of the scope of this work.

Given the very promising results obtained by the in vitro experiments using cell lines, we sought to investigate whether these results could also be observed in vivo, now investigating both the antitumoral activity and the toxicity of the formulation. We used a xenograft model, injecting A431 cells into the flank of immunosuppressed mice, as detailed in Supporting Information. When tumours reached 3 mm in diameter, mice were administered intraperitoneally twice weekly equimolar concentrations (4 mg/kg of derivative 1 and 5 mg/kg of derivative 2) of 1, 2, and 1:2 free or assembled in NP1, or solely the vehicle. Strikingly, when the derivative 2 is injected as a free drug, alone or together with 1, it induces very high toxicity and the mice die or have to be sacrificed due to weight loss and general health deterioration less than a week after treatment initiation (Figure 3A). The derivative 1 alone is not toxic, but does not have an effect on tumour growth. Although, when the same concentration of 1:2 is administered as self-assembled NPs, there is no toxicity and there is a significant delay in tumour growth compared to the control mice (Figure 3B).

Figure 2. Dose response of equimolar concentrations of CYP and DOXO as parental drugs (CYP:DOXO), conjugates (1:2) or assembled in nanoparticles (NP1). The effect on proliferation (A) and their cytotoxic potential (B) is estimated by FACS analysis of BrdU incorporation and cleaved PARP immunostaining respectively. Concentration of the samples: NP1 (nanoprecipitated CYP-SQ = DOXO-SQ = 10 μM); 1:2 (1:1): CYP-SQ = DOXO-SQ = 10 μM; CYP:DOXO (1:1): CYP = DOXO = 10 μM. Statistical significance (Student’s t test) compared to the control: ns, p>0.01; *, p < 0.01; **, p<0.001; ***, p<0.0001.

Figure 3. In vivo effect of equimolar concentration of CYP and DOXO conjugates, alone or in combination, or assembled in nanoparticles (NP1). (A) Kaplan Meier survival plot of mice upon treatment-administration, as indicated, twice weekly. Note that conjugate 2 alone or in combination with conjugate 1 exhibits high toxicity. (B) Follow up of tumour size over time, upon treatment as described in (A). 20 random images per tumour form 3 separate tumours were counted. (C) Representative immunofluorescence images of tumours from mice treated with NP1 or vehicle, stained with Keratin 14 indicating differentiated cancer cells and vimentin labeling tumour-associated fibroblasts and cells undergone epithelial-mesenchymal transition. Note the striking difference in the differentiation of the tumours. The antibodies are colour-coded. (D) Histogram illustrating the quantification of proliferating cells in mice treated with NP1 or vehicle, as illustrated in (C). Results are expressed as pH3+ cells per optical field.
of the samples: NP1: CYP-SQ = DOXO-SQ = 10 µM; 1:2(1:1): CYP-SQ = DOXO-SQ =10 µM; 1 = 10 µM; 2 = 10 µM. Statistical significance (Student’s t test): ns, p>0.01; ***, p<0.0001. Scale bars: Panel B, 100 µm; Panel E, 1000 µm.

Microscopic analysis of tumours from control mice and mice treated with NP1 3 weeks after treatment showed that the latter exhibit very strong inhibition of proliferation (Figure 3C, D), and a more differentiated phenotype (Figure 3E, F). The latter could have important implications in moderating the metastatic potential, although longer experiments should be performed to investigate this possibility. Therefore, our in vivo experiments unambiguously show that self-assembled NPs reduce tumour growth and toxicity of chemotherapy; this could enable the administration of higher doses, thus more effective cancer treatment.

In this paper we reported the formation of hetero-NPs combining cyclopamine- and doxorubicin-squalene derivatives. DLS characterization demonstrated that NPs are narrow monodisperse and stable for 4 weeks. In vitro biological evaluation on confirmed that the cytotoxic activity of the parental drugs is maintained. The efficacy of the nanoformulated drugs is higher than the single combination of the conjugates. Importantly, the in vivo experiments showed that cyclopamine-doxorubicin NPs not only reduce tumour growth, but also significantly decrease the toxicity of chemotherapy in mice. This will allow the administration of higher doses of chemotherapy, potentially eliminating the more resistant tumour cells and therefore leading to more effective treatment.

The results obtained demonstrated that the approach of the self-assembled hetero NPs is a promising way to treat different types of cancer cells and it makes possible to modulate the ratio of the combined drugs. Moreover, these results point out the possible application of this approach in the personalized therapy.

ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website.

AUTHOR INFORMATION
Corresponding Author
* E-mail: franco.dosio@unito.it
* E-mail: psotriop@ulb.ac.be
* E-mail: daniele.passarella@unimi.it

Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. *These authors contributed equally.

Funding Sources
P.A.S. is a chercheur qualifié of the FRS/FNRS. This work was supported by a research grant from the Fondation Contre le Cancer to P.A.S. This work was supported by MIUR - University of Turin Fondi Ricerca Locale (ex-60%). D.M. is supported by Fondazione Cariplo, grant n° 2014-1157. The generous contribution of AIRC (The Italian Association for Cancer Research) IG14536 to G.D. is gratefully acknowledged.

ACKNOWLEDGMENT
This research have been developed under the umbrella of COST Actions CM 1106 “Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells”. We express our gratitude to Emilio Caneva and Marco Pappini for the interesting discussions on the development of useful analytical methods for MS analysis. D.P. thanks PRIN 2012 “Identification, Synthesis and Study of Molecular Drugs Efficacy in Brain Tumor Treatment”

REFERENCES
(10) With the aim to confirm the maintenance of the biological activity of the parental drugs, and in particular of DOXO, the obtained NPs and the relative single conjugates 1 and 2 were first evaluated on 4 different cancer cell lines (A2780, IGROV, OVCAR432 and OVCAR433, see Supplementary Figure 3). The internalization was demonstrated by confocal microscopy on IGROV cells (Supplementary Figure 5).